Sustainability Report 2013 Lek d.d.

Company Profile Sustainability Report 2013 – Lek d.d. 10 1.3 About us Lek, a Sandoz company, is a joint-stock company, 100% owned by Novartis Pharma AG. It is based in Ljubljana, it has its development centers in Ljubljana and Menge‰ and operates at four production sites: in Ljubljana, Menge‰, Prevalje and Lendava. In 2013, all the sites became EMAS certified, and registered in the EMAS Register. 8 Lek develops, manufactures and markets effective, safe and quality medicinal products, from standard generic drugs through to state-of-the-art biosimilars. 9 For more information about Lek, please visit www.lek.si/en . Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affor- dable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 positi- on globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hor- monal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. For more information, please visit www.sandoz.com . * Sandoz is on Twitter. Follow @Sandoz_global at: http://twitter.com/sandoz . Novartis offers a highly diversified drug portfolio that address- es the evolving needs of patients and societies. It is the only global company with leading positions in the areas of innovative medicines, eye care products, affordable generic pharmaceuticals, preventative vaccines, diagnostic tools, over-the-counter and animal health products. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approxima- tely USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Headquartered in Basel, Switz- erland, Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com . * Novartis is on Twitter. Follow @Novartis at http://twitter.com/novartis . Lek is a pharmaceutical company, one of the pillars of Sandoz, the generic division of the Novartis Group and the second-largest global generics ma- nufacturer. Its role within Sandoz is to act as: • a leading Sandoz’ development center for products and technologies (medicinal products for oral use, injectables), • a global manufacturing center for active pharmaceutical ingredients and medicines (medicinal products for oral use, injectables), • a competence center for the development of vertically integrated products, • Center of Excellence in the field of development and manufacturing of biosimilar products, • one of the leading Sandoz’ global supply centers, responsible for sales on the Slovenian market and selling services for global Sandoz markets, • global IT competence center for production infor- mation systems; regional center for IT infrastruc- ture for countries of South-East Europe, Bulgaria in the Baltic region. 8 GRI Disclosures G4-5, G4-7 9 GRI Disclosure G4-4